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OBJECTIVES This study sought to evaluate the effectiveness and safety of the sirolimus-eluting stent in the
treatment of in-stent restenosis (ISR) in consecutive unselected patients undergoing coronary
intervention in a real-world scenario.
BACKGROUND Restenosis after bare metal stenting is characterized by a high rate of re-restenosis once
treated with repeated percutaneous coronary intervention.
METHODS The study was designed as a prospective two-center registry. We enrolled 244 patients with
ISR in a native coronary artery or saphenous vein graft who had clinical indication for repeat
intervention.
RESULTS Sirolimus stent implantation was successful in all lesions. At 9-month follow-up, death
occurred in 4 (1.6%) patients, myocardial infarction in 4 (1.6%), and ischemia-driven target
lesion revascularization (TLR) in 12 (4.9%), for a cumulative event-free survival of 227 (93%).
Although 9-month follow-up angiography was planned in all patients, only 150 (62%)
patients completed it, and restenosis was present in 13 (8.7%) patients. Diabetes and
non–ST-segment elevation acute coronary syndrome at presentation were the only indepen-
dent predictors of freedom from ischemia-driven TLR and major adverse cardiac events.
CONCLUSIONS Sirolimus stent implantation for the treatment of ISR is effective and safe. In diabetic patients
and in those with acute coronary syndrome, the higher rate of recurrence requires further
evaluation. (J Am Coll Cardiol 2006;48:270–5) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039Cardiology Foundation
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vn-stent restenosis (ISR) occurs at a rate of 15% to 50% after
he implantation of a bare-metal stent (BMS), depending
n patient subset, lesion characteristics, and type of stent
1). The recurrence after balloon angioplasty (percutaneous
oronary intervention [PCI]) treatment of ISR is approxi-
ately 40%, and it depends on the angiographic pattern at
resentation (2). Although the recent advent of drug-
luting stents (DES) significantly reduced the incidence of
SR in de novo coronary lesions even in high-risk patients
3–5), a policy of “DES them all” is difficult to apply in a
eal-world scenario because of the economic constraints we
ave to deal with. Consequently, BMS are still currently
sed and ISR remains a major challenge in daily practice.
everal catheter-based techniques have undergone experi-
entation in the treatment of ISR, and among them only
rachytherapy showed clinical benefit compared with stan-
ard balloon angioplasty (6–8). However, the significant
isk of edge restenosis and late acute thrombosis (9,10),
ogether with the need for a dedicated medical staff and
quipment, contributed to the decline of this technique.
After the evidence of restenosis reduction provided in de
ovo coronary lesions, DES have been tested in the treat-
From the *Cardiovascular Departments of San Donato Hospital, Arezzo, Italy; and
he †Le Scotte Hospital, Siena, Italy.w
Manuscript received December 19, 2005; revised manuscript received March 13,
006, accepted March 21, 2006.ent of ISR with positive results. Preliminary studies and
ecent registries of patients treated with sirolimus-eluting
tents (SES) to treat ISR-documented angiographic recur-
ence in 10% of patients (11–13). The goal of our registry
as to evaluate the long-term outcome of the results of
ystematic implantation of SES in a large series of consec-
tive patients with ISR treated in a real-world scenario and
o assess clinical and angiographic predictors of late
ecurrence.
ETHODS
he study was designed as a prospective single-arm 2-center
egistry to evaluate clinical outcome after the implantation
f SES for the treatment of ISR. From July 2002 to March
005, all patients presenting with ISR in a native vessel or
n vein graft with objective evidence of ischemia and
ithout clinical contraindication to prolonged double anti-
latelet therapy were enrolled in two centers (San Donato
ospital, Arezzo, Italy, and Le Scotte Hospital, Siena,
taly). There were no exclusion criteria, neither related to
linical presentation or stable or unstable patients, nor to
ngiographic characteristics such as vessel diameter or lesion
ength.
None of the patients had been previously treated with
essel brachytherapy, and all patients enrolled in the registry
ere first-restenosis patients. All patients gave written
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July 18, 2006:270–5 Sirolimus-Eluting Stent for In-Stent Restenosisnformed consent. The trial was approved by the institu-
ional ethics committees of the 2 participating centers.
tudy protocol and data analysis. All patients received a
olus of unfractionated heparin at a dose of 70 IU/kg before
tarting the procedure. Before SES implantation, balloon
redilation was performed in all target lesions with a balloon
f at least 2.5 mm in diameter. For the registry, SES lengths
f 8, 18, 23, 28, and 33 mm and diameters of 2.5 to 3.5 mm
ere available. Stent length was chosen to fully cover the
estenotic stent even when ISR was focal. In case of
wo-stent implantation, no gap between the stents was left.
n case of dissection because of a SES implantation, another
ES was always implanted to seal the dissected segment.
he SES were always implanted at high pressure (12
tm). Stent postdilation with a larger balloon was performed
nly in case of suboptimal results judged by visual
stimation.
Combined antiplatelet therapy with aspirin (at least 100
g daily) and ticlopidine 500 mg daily (or clopidogrel 75
g daily) was started at least 48 h before the procedure and
ontinued for at least 6 months. Glycoprotein IIb/IIIa
nhibitors were left to the operator’s discretion. Plasma
oncentrations of creatine kinase and its MB isoenzyme
ere systematically determined for 48 h after the interven-
ion. All patients were asked to return for a repeat coronary
ngiography at 9 months after the index coronary interven-
ion, and at specified intervals to the outpatient clinic for
ollow-up. Relevant data were collected and entered into a
omputer database.
ngiographic analysis. All angiograms were analyzed in a
andom sequence by two experienced observers who were
linded to the clinical characteristics of the patients. Coro-
ary angiograms were analyzed by a semiautomated edge
ontour detection computer analysis system (QCA CMS
ersion 4, Medis Medical Imaging Systems, Inc., Leiden,
he Netherlands). Manual editing of stenosis contours was
onsidered necessary by operators in a few cases with
ubocclusive complex coronary ISR. The ISR was classified
ccording to the angiographic patterns reported by Mehran
t al. (2). Reference diameter (RD), minimal lumen diam-
Abbreviations and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
ISR  in-stent restenosis
MACE  major adverse cardiac event
MI  myocardial infarction
NSTEACS  non–ST-segment elevation acute coronary
syndrome
OR  odds ratio
PCI  percutaneous coronary intervention
SES  sirolimus-eluting stent(s)
TIMI  Thrombolysis In Myocardial Infarction
TLR  target lesion revascularizationter (MLD), percentage diameter stenosis (DS), and lesion oength were measured before and at the end of the proce-
ure as well as at follow-up in those patients who underwent
-month angiography. Acute gain, late loss, and loss index
ere calculated using standard morphologic criteria.
ollow-up. After hospital discharge, patients were referred
o their private physicians, who regulated therapy. No
ttempt was made to standardize therapy, apart from the
ntithrombotic regimen. All patients were asked to return
o the outpatient clinic for evaluation by one of the
nvestigators 6 and 9 months after discharge. For those
atients who did not return to the clinic at the designated
ime, follow-up information was collected by telephone
nterview. All patients reporting symptoms of chest pain
ere requested to come to the outpatient clinic for
linical, electrocardiographic, laboratory, and eventually,
ngiographic assessment.
efinitions and outcome measures. Procedural success
as defined by the absence of a significant residual stenosis
ostprocedure, judged by operator visual estimation, with
hrombolysis In Myocardial Infarction (TIMI) flow grade
in the target vessel. Post-SES binary restenosis at
ollow-up was defined as 50% diameter stenosis occurring
n the segment inside the SES or within a 5-mm segment
roximal or distal to the stent.
Major adverse cardiac events (MACEs) were defined as
eath from any cause, nonfatal repeat acute myocardial
nfarction, and target lesion revascularization (TLR). Myo-
ardial infarction was defined as the presence of new Q
aves in 2 or more contiguous electrocardiography leads or
n elevation of creatine kinase or its MB isoenzyme to 3
imes the upper limit of normal in two samples during
ospitalization or to 2 times the upper limit of normal after
ischarge. The TLR was defined as any repeat PCI or
ortocoronary bypass surgery because of restenosis (DS
50%) within the stent or in the 5 mm distal or proximal
egments associated with symptoms or objective signs of
schemia (ischemia-driven TLR). We defined stent throm-
osis as the occurrence of any of the following events:
ngiographic documentation of partial or total stent occlu-
ion detected within 30 days of the procedure (an acute
linical ischemic event in addition to angiographic docu-
entation had to be present when the event occurred after
0 days), or sudden cardiac death or myocardial infarction
MI) after successful stent implantation not clearly attrib-
table to another coronary lesion. Primary end points of the
tudy were 9-month freedom from MACE and ischemia-
riven TLR.
tatistical analysis. Values are reported as numbers with
elative percentage or standard deviation. Nominal variables
ere compared using the Fisher exact test, continuous
ariables were compared with the t test. Logistic regression
as used to identify predictors of MACE, ischemia-driven
LR, and restenosis. The analysis included all baseline
ariables shown in Tables 1 and 2, considering the entire
opulation for the assessment of the independent predictors
f MACE and ischemia-driven TLR, and patients who
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Sirolimus-Eluting Stent for In-Stent Restenosis July 18, 2006:270–5ompleted follow-up angiography for the assessment of
ndependent predictors of restenosis. Odds ratio (OR) and
5% confidence intervals (CIs) were reported with two-
ailed probability value: a value of p  0.05 was considered
tatistically significant. Survival analysis was performed with
he Kaplan-Meier method in diabetic patients and those
resenting with non–ST-segment elevation acute coronary
yndrome (NSTEACS). All statistical computations were
able 1. Baseline Clinical Characteristics
Variable n (%)
atients 244
ge (yrs) 66  10
ale 188 (77)
amily history of CAD 86 (35)
iabetes 61 (25)
ypercholesterolemia 53 (22)
ypertension 72 (29)
urrent smoker 38 (16)
STEACS 73 (30)
ultivessel disease 98 (40)
revious MI 62 (25)
revious CABG 5 (2)
eft ventricular ejection fraction % 52  7 (range 25–65)
ata presented are numbers and relative percentages (%) and mean values  SD.
CAD  coronary artery disease; CABG  coronary artery bypass graft; MI 
yocardial infarction; NSTEACS  non–ST-segment elevation acute coronary
yndrome.
able 2. Procedural and Angiographic Characteristics
Variable n (%)
umber of target lesions 259
ultivessel intervention 54 (22)
ultivessel in-stent restenosis 15 (6)
arget vessel
Left anterior descending 119 (46)
Left circumflex 57 (22)
Right coronary artery 78 (30)
Saphenous vein graft 2 (1)
Left main 3 (1)
n-stent restenosis type
I 31 (12)
II 82 (32)
III 100 (38)
IV 46 (18)
D baseline, mm 2.99  0.32
LD baseline, mm 0.38  0.28
esion length baseline, mm 18.3  8.3
DS 87.2  9.8
LD after procedure, mm 2.94  0.33
otal stent length, mm 26.1  11.2
aximal pressure, atm 15.8  4.0
cute gain, mm 2.56  0.43
-month angiographic follow-up 150 (62)
RD, mm 2.97  0.31
MLD, mm 2.6  0.6
Late loss, mm 0.32  0.54
Late loss index 0.12  0.22
% DS 12.1  18.6
Restenosis (50) 13 (8.7)
ata presented are numbers and relative percentages (%) and mean values  SD.
DS  diameter stenosis; MLD  minimal lumen diameter; RD  reference
iameter.
n
rerformed using StatView (SAS Institute Inc., Cary, North
arolina) version 6 procedures.
ESULTS
aseline clinical and lesion characteristics. From July
002 to March 2005, 244 consecutive patients were enrolled
n the registry. The SES was successfully implanted in all
estenotic lesions. Follow-up angiography was performed in
50 patients (62%) at a mean time of 8.6  2.3 months.
easons for missing angiography were death or patient
efusal. All patients completed the clinical follow-up.
Baseline clinical characteristics of the entire population
re reported in Table 1. Seventy-three (30%) patients
resented with NSTEACS, and 61 (25%) patients had
iabetes. Angiographic and procedural characteristics of the
ntire population are reported in Table 2. Fifty-four (22%)
atients underwent multivessel intervention, and 15 (6%) of
hem had ISR in two different sites. Twenty-four patients
10%) needed more than one SES to entirely cover the
estenotic segment. All patients were discharge from the
ospital with aspirin and thienopyridine to be continued for
t least 6 months.
linical outcome. Clinical follow-up was obtained in all
atients at 9 months (Table 3). No MACE occurred during
ospitalization. Death occurred in four patients (mean age
7.7  11.3 years) and it was cardiac-related in three of
hem: one patient experienced a sudden death 3 months
fter SES implantation in an unprotected left main reste-
osis, one patient died for MI not related to the culprit
esion, and the last patient with severe left ventricle systolic
ysfunction died of heart failure. The remaining patient
ied of lung cancer. Nonfatal MI occurred in four patients,
nd it was related to SES thrombosis in one of them, plaque
hrombosis in the target vessel far from the SES implanted
n two patients, and thrombosis of a nonculprit vessel in one
atient. Ischemia-driven TLR was performed in 12 (4.9%)
atients (PCI in 11 patients and coronary artery bypass graft
n 1 patient). A total of 227 (93%) patients did not
xperience any event on long-term follow-up. An SES
hrombosis occurred in two patients: the patient who died
uddenly 3 months after the procedure and the patient who
xperienced a nonfatal MI because of stent thrombosis
ocumented by coronary angiography. Logistic regression
able 3. Cumulative In-Hospital and 9-Month Clinical
utcomes
n (%)
eath 4 (1.6)
onfatal MI 5 (2)
schemia-driven repeated revascularization
TLR 12 (4.9)
TVR 15 (6.1)
PCINTL 11 (4.5)
-month event free 227 (93)
I  myocardial infarction; PCINTL  percutaneous coronary intervention of a
ontarget lesion; TLR  target lesion revascularization; TVR  target vessel
evascularization (including TLR).
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July 18, 2006:270–5 Sirolimus-Eluting Stent for In-Stent Restenosisnalysis showed that the presence of diabetes (OR 0.19,
5% CI 0.052 to 0.68 for freedom from TLR, p 0.01, and
R 0.17, 95% CI 0.05 to 0.68 for freedom from MACE,
 0.002) and acute coronary syndrome at presentation
OR 0.18, 95% CI 0.047 to 0.70 for freedom from TLR,
 0.01 and OR 0.26, 95% CI 0.08 to 0.87 for freedom
rom MACE, p 0.01) significantly reduced freedom from
schemia-driven TLR and MACE.
ngiographic outcome. Follow-up angiography was per-
ormed in 150 (62%) patients with 158 lesions at a mean
ime of 8.6  2.3 months (Table 2). Late loss was 0.32 
.54 mm. Cumulative distribution curve of angiographic
ate loss (Fig. 1) shows that the vast majority of the lesions
80%) had a late loss between 0.20 and 0.35 mm. Overall,
ost-SES restenosis was observed in 13 (8.7%) patients.
he restenotic pattern was focal in 9 lesions, proliferative in
lesions, and totally occluded in 2 lesions. Of the patients
ith an occluded target vessel at follow-up angiography,
ubacute occlusive thrombosis with nonfatal MI developed
n one and the other had an angiographic documentation of
essel occlusion not preceded by an acute coronary syn-
rome. Logistic regression analysis performed in the 150
atients with angiographic follow-up documented lesion
ength as the only angiographic independent predictor of
-month restenosis (OR 1.16, 95% CI 1.09 to 1.31, p 
igure 1. Cumulative distribution of late loss at angiographic follow-up.
estenosis and ischemia-driven target lesion revascularization (TLR) is
eported corresponding to the respective late loss value for each lesion.igure 2. (A) Kaplan-Meier analysis for 9-month major adverse cardiac event
eier analysis for survivals free from 9-month ischemia-driven target lesion rev.03) and diabetes (OR 3.21, 95% CI 1.01 to 6.4, p 0.01),
nd NSTEACS at presentation (OR 2.89, 95% CI 1.16 to
.6, p  0.01) as clinical independent predictors of
estenosis.
ubgroup analysis. We performed subgroup analysis to
stimate the treatment effect within diabetic patients and
atients with ISR and NSTEACS.
Sixty-one (25%) patients were diabetic, mean age 68 
0 years. These patients experienced a higher rate of clinical
vents compared with nondiabetic patients: ischemia-driven
LR 7 (11.6%) versus 5 (2.7%) (p  0.01), MACE 10
16.6%) versus 7 (3.8%) (p  0.001), respectively. Figure 2
hows Kaplan-Meier survival analysis for freedom from
ACE (Fig. 2A) and ischemia-driven TLR (Fig. 2B).
ollow-up angiographic restenosis was present in 7 of 40
17.5%) diabetic patients versus 6 of 110 (5.4%) in nondi-
betic patients (p 0.04) and lesion late loss was 0.70 1.0
ersus 0.26  0.6, p  0.01, respectively.
In this registry, 73 (30%) patients (mean age 69.4  11
ears) presented with NSTEACS as an indication to SES
mplantation for ISR lesions. Diabetes was equally distrib-
ted among these patients (25%) and patients with stable
ngina (24.5%) (p  0.9). The NSTEACS patients expe-
ienced a higher rate of clinical events during follow-up
ompared with patients who presented with stable angina:
schemia-driven TLR 8 (11.1%) versus 4 (2.3%) (p 
.007), MACE 10 (13.8%) versus 7 (4%) (p  0.01),
espectively. Figure 3 shows Kaplan-Meier survival analysis
or freedom from MACE (Fig. 3A) and ischemia-driven
LR (Fig. 3B). Follow-up angiographic restenosis was
resent in 9 of 43 (20.9%) NSTEACS patients versus 4 of
07 (3.7%) in stable angina patients (p  0.001), and lesion
ate-loss was 0.79  1.1 versus 0.19  0.5, p  0.01,
espectively.
ISCUSSION
o our knowledge this registry is the largest series of
atients treated with SES for ISR lesions in a real-world
cenario with no exclusion criteria concerning patients’
linical status as well as angiographic criteria. The SES(MACE)-free survivals in diabetic and nondiabetic patients. (B) Kaplan-
ascularization (TLR) in diabetic and nondiabetic patients.
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Sirolimus-Eluting Stent for In-Stent Restenosis July 18, 2006:270–5mplantation was successful in all patients, and an optimal
ngiographic result was possible in all of the target lesions.
he results at 9-month follow-up confirm the efficacy of
ES in the prevention of recurrences with an ischemia-
riven TLR rate of 4.9% significantly lower than those
eported in similar settings with balloon angioplasty (TLR
ate 20% to 40%) (14–16) and coronary brachytherapy
TLR rate 15%–20%) (6,9,17–19). Our data also compare
avorably with a previous study focusing the results of SES
mplantation in ISR lesions: 8% TLR in the sirolimus arm
100 patients) of the ISAR-DESIRE (Intracoronary Stent-
ng and Angiographic Results Drug-Eluting Stents for
n-Stent Restenosis) study (20), 7.4% TLR reported in the
ROPICAL (Multicenter, Nonrandomized Sirolimus-
luting Stent in the Treatment of Patients with an In-Stent
estenotic Native Coronary Artery Lesion) registry (150 pa-
ients) (12), 11.6% TLR in the RESEARCH (Rapamycin-
luting Stent Evaluated at Rotterdam Cardiology Hospital)
egistry (11), and 8% TLR in the study (136 patients) by
igliorini et al. (13). These differences might be explained
y the percentage of angiographic follow-up reported in our
egistry (62%) compared with that reported in most of those
tudies (90%). The TLR rate of these trials might have
een artificially inflated by reinterventions because of ultra-
ound or angiographic findings not always clinically driven
r justified by predefined angiographic criteria.
In our registry, the presence of diabetes and NSTEACS
s an indication to PCI were independent predictors of
-month ischemia-driven TLR as well as 9-month MACE.
here was also a significantly higher restenosis and late loss
n these subgroups compared with patients who did not
ave these clinical variables. The higher rate of restenosis
nd clinical recurrence in patients with diabetes is reported
n several studies with DES for de novo coronary lesions
21,22), and it has been related to an exaggerated intimal
roliferative response to stent-related trauma proper of
iabetic patients. The higher ischemia-driven TLR rate
bserved in unstable patients is also reported in previous
rials concerning the use of SES for ISR (13,23). It is
igure 3. (A) Kaplan-Meier analysis for 9-month major adverse cardiac e
oronary syndrome (NSTEACS) and in those with stable angina. (B) Kapl
evascularization (TLR) in NSTEACS patients and in those with stable aossible that the inflammatory status of the target lesion in uatients with unstable angina may produce an intensive
ntimal response to SES implantation resulting in a higher
ate of recurrence. Thus, these data suggest that patients
ith diabetes and unstable angina undergoing SES implan-
ation for ISR lesions should be scheduled for 9-month
oronary angiography because of the high rate of recurrence.
No clear differences in the rates of repeat restenosis were
oted among higher-risk categories (that is, Mehran classes
I, III, and IV), in which the rates of repeat restenosis are
igh with conventional treatment. Thus, it is possible that
ES implantation reduces the prognostic value of the ISR
attern for nonfocal ISR, although the limited number of
ur observations does not allow a definitive conclusion.
onversely, our data suggest that lesion length may still
ave an impact on recurrent restenosis.
In our registry, SES for ISR lesions showed an acceptable
afety profile, and stent thrombosis was observed in two
0.8%) patients, sensibly lower than that reported with
oronary brachytherapy (24).
tudy limitations. The rate of angiographic follow-up
62% of patients), although similar to that of other registries
hat enrolled patients with recurrent ISR (RESEARCH
egistry), is insufficient to allow for determination of the true
inary restenosis rate for the entire cohort. Actually, the low
ngiographic follow-up rate does not affect the clinical
elevance of the data because all patients without angio-
raphic follow-up were free from symptoms and inducible
schemia. On the other hand, a higher angiographic
ollow-up rate would have allowed for more reliable infor-
ation on restenosis rate, but not on the incidence of
schemia-driven TLR, one of the major end points of the
egistry.
Because of the unavailability in our hospitals of coronary
rachytherapy equipment, we could not compare in any
ashion, randomized or nonrandomized, our results with
hose achievable with this technique. However, our data
uggest a greater efficacy and safety profile with SES
ompared with historical data (6,9,18,19) concerning the
MACE)-free survivals in patients with non–ST-segment elevation acute
eier analysis for survivals free from 9-month ischemia-driven target lesion
.vent (
an-Mse of brachytherapy in the treatment of ISR lesions.
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July 18, 2006:270–5 Sirolimus-Eluting Stent for In-Stent Restenosisonclusions. Systematic use of SES to treat ISR seemed
afe und effective in unselected series of consecutive patients
reated in a real-world scenario providing a very low
-month ischemia-driven TLR and MACE rate. In pa-
ients with diabetes and in those presenting with unstable
ngina, SES seemed to be less efficacious. Further analysis
ith larger series and more prolonged follow-up, as well as
direct comparison with brachytherapy in a randomized
ashion, will provide further scientific information regarding
ES effectiveness in these settings.
eprint requests and correspondence: Dr. Francesco Liistro,
epartment of Cardiovascular Disease, San Donato Hospital, Via
ietro Nenni 22, Arezzo, 52100, Italy. E-mail: francescoliistro@
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